热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　科济药业-B（02171）盘中涨超7%，截至发稿，股价上涨5.32%，现报16.83港元，成交额5248.14万港元。

　　7月16日，科济药业宣布，根据国家医保局的公告显示，恺力美®（舒瑞基奥仑赛注射液，产品编号：CT041，一种靶向Claudin18.2的自体CAR-T细胞治疗候选产品）已顺利通过2026年国家商业健康保险创新药品目录调整初步形式审查。作为全球首款获批上市的实体瘤CAR-T疗法，该产品实现了细胞免疫治疗从血液瘤到实体瘤的历史性跨越，精准填补了晚期胃癌治疗临床空白。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.